onr:"swepub:oai:DiVA.org:uu-450118"
Sökning: onr:"swepub:oai:DiVA.org:uu-450118" > Rethinking the Appl...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Rethinking the Application of Pemetrexed for Patients with Renal Impairment : A Pharmacokinetic Analysis
-
- de Rouw, Nikki (författare)
- Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Pharm, POB 9101, NL-6500 HB Nijmegen, Netherlands.;Jeroen Bosch Hosp, Dept Pharm, Shertogenbosch, Netherlands.
-
- Boosman, Rene J. (författare)
- Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.
-
- Huitema, Alwin D. R. (författare)
- Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.;Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands.
- visa fler...
- visa färre...
- Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Pharm, POB 9101, NL-6500 HB Nijmegen, Netherlands;Jeroen Bosch Hosp, Dept Pharm, Shertogenbosch, Netherlands. Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands. (creator_code:org_t)
- 2021-01-09
- 2021
- Engelska.
- Ingår i: Clinical Pharmacokinetics. - : ADIS INT LTD. - 0312-5963 .- 1179-1926. ; 60:5, s. 649-654
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Background Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is well tolerated in this population. Objective The purpose of our study was to investigate the pharmacokinetics (PK) of pemetrexed in patients with renal impairment. Methods A population PK analysis of pemetrexed was performed using non-linear mixed-effects modelling with phase I data obtained from the manufacturer. Additionally, the impact of renal function on pemetrexed PK was assessed with a simulation study using the developed PK model and a previously developed PK model lacking the phase I data. Results The dataset included 548 paired observations of 47 patients, with a wide range of estimated glomerular filtration rates (eGFR; 14.4-145.6 mL/min). Pemetrexed PK were best described by a three-compartment model with eGFR (calculated using the Chronic Kidney Disease-Epidemiology Collaboration [CKD-EPI] formula) as a linear covariate on renal pemetrexed clearance. Using the developed model, we found that renal clearance accounts for up to 84% (95% confidence interval 69-98%) of total pemetrexed clearance, whereas the manufacturer previously reported a 50% contribution of renal clearance. Conclusion Renal function is more important for the clearance of pemetrexed than previously thought and this should be taken into account in patients with renal impairment. Furthermore, a third compartment may contribute to prolonged exposure to pemetrexed during drug washout.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
- Clinical Pharmacokinetics (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- de Rouw, Nikki
- Boosman, Rene J.
- Huitema, Alwin D ...
- Hilbrands, Luuk ...
- Svensson, Elin, ...
- Derijks, Hierony ...
- visa fler...
- van den Heuvel, ...
- Burger, David M.
- ter Heine, Rob
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Urologi och njur ...
- Artiklar i publikationen
- Clinical Pharmac ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
